---
document_datetime: 2025-10-07 15:10:20
document_pages: 6
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps-after/benlysta-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
document_name: benlysta-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
version: success
processing_time: 3.0607526
conversion_datetime: 2025-12-20 08:17:09.342674
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.64.1
  docling-core: 2.55.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
## Benlysta

Procedural steps taken and scientific information after the authorisation*

*Due to the Agency`s update of its procedure management systems, an additional document, reflecting the historical lifecycle may be available in the 'Assessment history' section. For the complete product lifecycle procedures, you may need to also refer to EPAR - Procedural steps taken and scientific information after authorisation (archive) .

| Application number                    | Scope                                              | Opinion/ Notification 1 issued on   | Commission Decision Issued 2 / amended on   | Product Information affected 3   | Summary                                                                                                                                         |
|---------------------------------------|----------------------------------------------------|-------------------------------------|---------------------------------------------|----------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------|
| Variation type II / EMA/VR/0000286149 | This was an application for a group of variations. | 25/09/2025                          |                                             | Annex II                         | The Annex II has been updated to include the additional manufacturer of the active substance - Human Genome Sciences, Inc. (Belward Small Scale |

1  Notifications are issued for type I variations and Article 61(3) notifications (unless part of a group including a type II variation or extension application or a worksharing application). Opinions are issued for all other procedures.

2  A Commission decision (CD) is issued for procedures that affect the terms of the marketing authorisation (e.g. summary of product characteristics, annex II, labelling, package leaflet). The CD is issued within two months of the opinion for variations falling under the scope of Article 23.1a(a) of Regulation (EU) No. 712/2012, or within one year for other procedures.

3  SmPC (Summary of Product Characteristics), Annex II, Labelling, PL (Package Leaflet).

<!-- image -->

<!-- image -->

<div style=\"page-break-after: always\"></div>

| B.I.a.1 Change in the manufacturer of starting in the manufacturing process of the                                                                                                                                                                                                                                                                                                                                                                                                                                                                              | a material/reagent/intermediate used active   |
|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------|
| B.I.a.1 Change in the manufacturer of a starting material/reagent/intermediate used in the manufacturing process of the active substance or change in the manufacturer (including where relevant quality control testing sites) of the active substance, where no Ph. Eur. Certificate of Suitability is part of the approved dossier - B.I.a.1.e The change relates to a biological active substance or a starting material/reagent/intermediate used in the manufacture of a biological/immunological product - Accepted B.I.a.2 Changes in the manufacturing |                                               |
| process of the active substance - B.I.a.2.c                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |                                               |
| The change refers to a biological /                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |                                               |

<div style=\"page-break-after: always\"></div>

| different chemically derived substance in the manufacture of a biological/immunological substance, which may have a significant impact on the quality, safety and efficacy of the medicinal product and is not related to a protocol - Accepted B.I.a.2 Changes in the manufacturing process of the active substance - B.I.a.2.c The change refers to a biological / immunological substance or use of a different chemically derived substance in the manufacture of a biological/immunological substance, which may have a significant impact on the quality, safety and efficacy of the medicinal product and is not related to a protocol - Accepted B.I.b.2 Change in test procedure for active substance or starting material/reagent/intermediate used in the manufacturing process of the active substance - B.I.b.2.d Substantial change to or replacement of a biological/ immunological/ immunochemical test method or a method using a biological reagent for a biological active substance - Accepted B.I.b.1 Change in the specification   |
|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

<div style=\"page-break-after: always\"></div>

|                                       | reagent used in the manufacturing process of the active substance - B.I.b.1.e Deletion of a specification parameter which may have a significant effect on the overall quality of the active substance and/or the finished product - Accepted                                                                                                                                                                                                                                                                                                                                         |            |     |
|---------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|
| Variation type IB / EMA/VR/0000294571 | B.II. FINISHED PRODUCT - B.II.z To update Module 3.2.A.1 for a biotech medicinal product - Accepted                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   | 19/09/2025 | N/A |
| Variation type II / EMA/VR/0000281374 | This was an application for a group of variations. B.I.b.1 Change in the specification parameters and/or limits of an active substance, starting material / intermediate / reagent used in the manufacturing process of the active substance - B.I.b.1.f Change outside the approved specifications limits range for the active substance - Accepted B.II.b.5 Change to in-process tests or limits applied during the manufacture of the finished product - B.II.b.5.z Other changes - Accepted B.II.d.2 Change in test procedure for the finished product - B.II.d.2.d Other changes | 11/09/2025 | N/A |

<div style=\"page-break-after: always\"></div>

|                                       | or addition) - Accepted B.II.d.1 Change in the specification parameters and/or limits of the finished product - B.II.d.1.e Change outside the approved specifications limits range - Accepted B.I.b.2 Change in test procedure for active substance or starting material/reagent/intermediate used in the manufacturing process of the active substance - B.I.b.2.e Other changes to a test procedure (including replacement or addition) for the active substance or a starting material/intermediate - Accepted B.I.b.2 Change in test procedure for active substance or starting material/reagent/intermediate used in the manufacturing process of the active substance - B.I.b.2.e Other changes to a test procedure (including replacement or addition) for the active substance or a   |            |     |
|---------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|
| Variation type IB / EMA/VR/0000258237 | B.I.a.4 Change to in-process tests or limits applied during the manufacture of the active substance - B.I.a.4.z Other variation - Accepted                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    | 11/04/2025 | N/A |

<div style=\"page-break-after: always\"></div>

| Variation type IB / EMA/VR/0000246395   | B.I ACTIVE SUBSTANCE - B.I.z Other variation - Accepted   | 18/02/2025   | N/A   |
|-----------------------------------------|-----------------------------------------------------------|--------------|-------|